The new Ultra incorporates vacuum massage and infra red skin tightening to target more stubborn fatty deposits, enhance lymphatic drainage and promote skin renewal to improve the appearance of cellulite..
Chromogenex’s i-Lipo system has just won the “Best Slimming Treatment” award at “Les Victoires de la Beauté” in France.
i-Lipo uses low levels of visible red laser light to create a safe and painless bio-stimulation effect in the targeted fat tissue. This stimulation is of the normal chemical pathways which the body uses to free up energy resources when required, so i-Lipo does not produce any abnormal effects in the body or damage body tissue such as cells, blood vessels or neighboring nerves or vital organs. The treatment can be performed on all skin types and body areas where unwanted fat is stored and you can return to normal activity immediately after treatment.
Results can be seen immediately after treatment. Typically a 2-4cm loss in abdomen circumference can be achieved with every treatment. A course of 8 treatments is recommended over 4 weeks with 2 treatments per week. Comparable results for any body area treated.
i-Lipo can target fat reduction in specific problem areas. By positioning the laser pads on an area such as chin, upper arms, abdomen or thighs, fat can be broken down and removed specifically from that area. This is a great advantage over diet and exercise which can reduce overall body fat, but not shape individual areas.
Chromogenex Receives FDA Clearance for Circumferential Reduction for i-Lipo Body Contouring System
Newly introduced to U.S. market, successful system is leading option for physicians treating fat reduction non-surgically.
NEW YORK, NY – Chromogenex announced today that they have received FDA approval to market the i-Lipo low-level laser diode device for circumferential reduction of the waist. i-Lipo is the first direct skin contact laser device designed for fat reduction and body contouring to receive FDA approval for circumference reduction. Based on results from a recent double-blind, placebo-controlled, randomized study of 34 volunteers, the FDA found that over 70% of participants experienced significant inch loss, thus validating the use of i-Lipo to target specifically chosen anatomical areas for fat reduction. The results represented more than double the percentage difference for meeting significant results as defined by the FDA.
“This study supports previous studies completed in France and the UK and from results experienced by current i-Lipo devices already placed in over 1000 commercial clinics worldwide,” stated Peter McGuinness, CEO of Chromogenex Technologies LTD. “This result from the FDA is extremely statistically significant and gives confidence of 99.99% that a participant undertaking i-Lipo will achieve a greater circumference reduction than a participant undertaking exercise alone in a three to four week period.”